Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90%
October 21, 2022 07:48 ET
|
Matinas BioPharma Holdings, Inc.
Two-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203 Mean Early Fungicidal Activity (EFA) of the rate of yeast clearance in cerebrospinal fluid exceeded the...
Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
October 20, 2022 17:15 ET
|
Summit Therapeutics Inc.
Ridinilazole resulted in a 53% relative risk reduction in recurrence of C. difficile infection compared to treatment with vancomycin Ridinilazole preserved the gut microbiome compared to...
Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022
October 19, 2022 07:10 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
October 13, 2022 08:00 ET
|
Summit Therapeutics Inc.
Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and its product candidate, ridinilazole, will have an oral podium...
Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022
October 12, 2022 07:00 ET
|
Matinas BioPharma Holdings, Inc.
Interim data from all-oral Cohort 4 of the EnACT Trial of MAT2203 in Cryptococcal Meningitis to be revealed along with an overview of the entire Phase 2 trial Late-breaking data demonstrate that...
Summit Therapeutics Provides Update on Ridinilazole
July 14, 2022 08:30 ET
|
Summit Therapeutics Inc.
Menlo Park, CA, July 14, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today provided an update with respect to the clinical development of...
Summit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investigational Drug Ridinilazole During IDWeek 2021
September 30, 2021 09:00 ET
|
Summit Therapeutics Inc.
Cambridge, Massachusetts, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying an important ePoster at IDWeek 2021. IDWeek is...
Melinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program
October 05, 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
VBI Vaccines’ Late-Breaker Cytomegalovirus Abstract Chosen for Oral Presentation at IDWeek 2018
October 02, 2018 08:00 ET
|
VBI Vaccines, Inc.
Presentation to feature complete safety and immunogenicity dataset from the Phase 1 clinical study of VBI-1501Oral presentation at IDWeek 2018 on Saturday, October 6th, 2018, at 11:10 AM PDT ...
Melinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeek
October 04, 2017 13:13 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...